{
  "resourceType": "Bundle",
  "identifier": {
    "system": "urn:ietf:rfc:3986",
    "value": "urn:uuid:a8201808-3647-4557-9235-c90dda85d65c"
  },
  "type": "document",
  "timestamp": "2025-06-01T09:10:44.248867Z",
  "entry": [
    {
      "fullUrl": "https://www.example.com/Composition/1234",
      "resource": {
        "resourceType": "Composition",
        "status": "preliminary",
        "type": {
          "text": "EvidenceReport"
        },
        "date": "2025-06-01T09:10:44.248867Z",
        "author": [
          {
            "display": "USDM"
          }
        ],
        "title": "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease",
        "section": [
          {
            "title": "TITLE PAGE",
            "code": {
              "text": "section0-title-page"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><table><tr><th style=\"vertical-align: top; text-align: left\"><p>Sponsor Confidentiality Statement:</p></th><td style=\"vertical-align: top; text-align: left\"><p></p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Full Title:</p></th><td style=\"vertical-align: top; text-align: left\"><p>Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Trial Acronym:</p></th><td style=\"vertical-align: top; text-align: left\"><p>H2Q-MC-LZZT</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Protocol Identifier:</p></th><td style=\"vertical-align: top; text-align: left\"><p>H2Q-MC-LZZT</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Original Protocol:</p></th><td style=\"vertical-align: top; text-align: left\"><p></p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Version Number:</p></th><td style=\"vertical-align: top; text-align: left\"><p>2</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Version Date:</p></th><td style=\"vertical-align: top; text-align: left\"><p>2006-06-01</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Amendment Identifier:</p></th><td style=\"vertical-align: top; text-align: left\"><p>1</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Amendment Scope:</p></th><td style=\"vertical-align: top; text-align: left\"><p>Global</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Compound Codes(s):</p></th><td style=\"vertical-align: top; text-align: left\"><p></p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Compound Name(s):</p></th><td style=\"vertical-align: top; text-align: left\"><p></p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Trial Phase:</p></th><td style=\"vertical-align: top; text-align: left\"><p>Phase II Trial</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Short Title:</p></th><td style=\"vertical-align: top; text-align: left\"><p>Xanomeline (LY246708)</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Sponsor Name and Address:</p></th><td style=\"vertical-align: top; text-align: left\"><p>Eli Lilly, Lilly Corporate Ctr, Indianapolis, , IN, 4628, United States of America</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Regulatory Agency Identifier Number(s):</p></th><td style=\"vertical-align: top; text-align: left\"><p>NCT12345678</p></td></tr><tr><th style=\"vertical-align: top; text-align: left\"><p>Spondor Approval Date:</p></th><td style=\"vertical-align: top; text-align: left\"><p>2006-07-01</p></td></tr></table></div>"
            },
            "section": []
          },
          {
            "title": "PROTOCOL SUMMARY",
            "code": {
              "text": "section1-protocol-summary"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Protocol Synopsis",
            "code": {
              "text": "section1.1-protocol-synopsis"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Trial Schema",
            "code": {
              "text": "section1.2-trial-schema"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Schedule of Activities",
            "code": {
              "text": "section1.3-schedule-of-activities"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><div class=\"page soa-page table-responsive\"><p><b>Timeline: Vital Sign Blood Pressure Timeline, Automatic execution</b></p><table class=\"table table-bordered table-sm\" style=\"width:100%\"><tr><td><p class=\"soa-activity-text\"></p></td><td><p class=\"soa-body-text\">BP Anchor</p></td><td><p class=\"soa-body-text\">BP while Supine</p></td><td><p class=\"soa-body-text\">BP Stand Up</p></td><td><p class=\"soa-body-text\">BP while standing</p></td></tr><tr><td><p class=\"soa-activity-text\"></p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\">-2..0 min</p></td><td><p class=\"soa-body-text\"></p></td></tr><tr><td><p class=\"soa-activity-text\">Supine for 5 minutes</p></td><td><p class=\"soa-body-text\">X</p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\"></p></td></tr><tr><td><p class=\"soa-activity-text\">Blood pressure supine</p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\">X</p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\"></p></td></tr><tr><td><p class=\"soa-activity-text\">Stand for 3 minutes</p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\">X</p></td><td><p class=\"soa-body-text\"></p></td></tr><tr><td><p class=\"soa-activity-text\">Blood pressure standing</p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\"></p></td><td><p class=\"soa-body-text\">X</p></td></tr></table></div></div>"
            },
            "section": []
          },
          {
            "title": "INTRODUCTION",
            "code": {
              "text": "section2-introduction"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Purpose of Trial",
            "code": {
              "text": "section2.1-purpose-of-trial"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Summary of Benefits and Risks",
            "code": {
              "text": "section2.2-summary-of-benefits-and-risks"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS",
            "code": {
              "text": "section3-trial-objectives,-endpoints-and-estimands"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Primary Objectives",
            "code": {
              "text": "section3.1-primary-objectives"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><table><tr><td style=\"vertical-align: top; text-align: left\"><p>To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).</p></td><td style=\"vertical-align: top; text-align: left\"><p>Alzheimer's Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Week 24</p><p>Video-referenced Clinician\u2019s Interview-based Impression of Change (CIBIC+) at Week 24</p></td></tr><tr><td style=\"vertical-align: top; text-align: left\"><p>To document the safety profile of the xanomeline TTS.</p></td><td style=\"vertical-align: top; text-align: left\"><p>Adverse events</p><p>Vital signs (weight, standing and supine blood pressure, heart rate)</p><p>Laboratory evaluations (Change from Baseline)</p></td></tr><tr><td style=\"vertical-align: top; text-align: left\"><p>To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in theseareas.</p></td><td style=\"vertical-align: top; text-align: left\"><p>Alzheimer's Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Weeks 8 and 16</p><p>Video-referenced Clinician\u2019s Interview-based Impression of Change (CIBIC+) at Weeks 8 and 16</p><p>Mean Revised Neuropsychiatric Inventory (NPI-X) from Week 4 to Week 24</p></td></tr></table></div>"
            },
            "section": []
          },
          {
            "title": "TRIAL DESIGN",
            "code": {
              "text": "section4-trial-design"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Description of Trial Design",
            "code": {
              "text": "section4.1-description-of-trial-design"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Temperature</div>"
            },
            "section": []
          },
          {
            "title": "Participant Input into Design",
            "code": {
              "text": "section4.1.1-participant-input-into-design"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Rationale for Trial Design",
            "code": {
              "text": "section4.2-rationale-for-trial-design"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Previous studies of the oral formulation have shown that xanomeline tartrate may improve behavior and cognition. Effects on behavior are manifest within 2 to 4 weeks of initiation of treatment. The same studies have shown that 8 to 12 weeks are required to demonstrate effects on cognition and clinical global assessment. This study is intended to determine the acute and chronic effects of the TTS formulation in AD; for that reason, the study is of 26 weeks duration. Dosage specification has been made on the basis of tolerance to the xanomeline TTS in a clinical pharmacology study (H2Q-EW-LKAA), and target plasma levels as determined in studies of the oral formulation of xanomeline (H2Q-MC-LZZA).</p></div>"
            },
            "section": []
          },
          {
            "title": "Rationale for Comparator",
            "code": {
              "text": "section4.2.1-rationale-for-comparator"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The parallel dosing regimen maximizes the ability to make direct comparisons between the treatment groups. The use of placebo allows for a blinded, thus minimally biased, study. The placebo treatment group is a comparator group for efficacy and safety assessment.</p><p>Two interim analyses are planned for this study. The first interim analysis will occur when 50% of the patients have completed Visit 8 (8 weeks). If required, the second interim analysis will occur when 50% of the patients have completed Visit 12 (24 weeks).</p></div>"
            },
            "section": []
          },
          {
            "title": "Rationale for Adaptive or Novel Trial Design",
            "code": {
              "text": "section4.2.2-rationale-for-adaptive-or-novel-trial-design"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Other Trial Design Considerations",
            "code": {
              "text": "section4.2.3-other-trial-design-considerations"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Access to Trial Intervention After End of Trial",
            "code": {
              "text": "section4.3-access-to-trial-intervention-after-end-of-trial"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Start of Trial and End of Trial",
            "code": {
              "text": "section4.4-start-of-trial-and-end-of-trial"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "TRIAL POPULATION",
            "code": {
              "text": "section5-trial-population"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Selection of Trial Population",
            "code": {
              "text": "section5.1-selection-of-trial-population"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>For Lilly studies, the following definitions are used:</p><div><div><strong>Screen</strong></div><div><p>Screening is the act of determining if an individual meets minimum requirements to become part of a pool of potential candidates for participation in a clinical study.</p><p>In this study, <strong>screening</strong> will include asking the candidate preliminary questions (such as age and general health status) and conducting invasive or diagnostic procedures and/or tests (for example, diagnostic psychological tests, x-rays, blood draws). Patients will sign the consent at their screening visit, thereby consenting to undergo the screening procedures and to participate in the study if they qualify.</p></div></div><div><div>To <strong>enter</strong></div><div><p>Patients <strong>entered</strong> into the study are those from whom informed consent for the study has been obtained. Adverse events will be reported for each patient who has <strong>entered</strong> the study, even if the patient is never assigned to a treatment group (<strong>enrolled</strong>).</p></div></div></div><div><div>To <strong>enroll</strong></div><div><p>Patients who are enrolled in the study are those who have been assigned to a treatment group. Patients who are entered into the study but fail to meet criteria specified in the protocol for treatment assignment will not be enrolled in the study.</p></div></div><p>At Visit 1, patients who meet the enrollment criteria of Mini-Mental State Examination (MMSE) score of 10 to 23 (Attachment LZZT.6), Hachinski Ischemia Score \u22644 (Attachment LZZT.8), a physical exam, safety labs, ECG, and urinalysis, will proceed to Visit 2 and Visit 3. At Visit 3, patients whose CNS imaging and other pending labs from Visit 1 satisfy the inclusion criteria (Section 3.4.2.1) will be enrolled in the study. Approximately 300 patients with a diagnosis of probable mild to moderate AD will be enrolled in the study.</p>"
            },
            "section": []
          },
          {
            "title": "Rationale for Trial Population",
            "code": {
              "text": "section5.2-rationale-for-trial-population"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Inclusion Criteria",
            "code": {
              "text": "section5.3-inclusion-criteria"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Patients may be included in the study only if they meet <strong>all</strong> the following criteria:</p><table><tr><td style=\"vertical-align: top; text-align: left\"><p>1</p></td><td style=\"vertical-align: top; text-align: left\"><p>Subjects shall be between id='Quantity_13' extensionAttributes=[] value=50.0 unit=AliasCode(id='AliasCode_236', extensionAttributes=[], standardCode=Code(id='Code_577', extensionAttributes=[], code='C29848', codeSystem='http://www.cdisc.org', codeSystemVersion='2024-09-27', decode='Year', instanceType='Code'), standardCodeAliases=[], instanceType='AliasCode') instanceType='Quantity' and id='Quantity_14' extensionAttributes=[] value=100.0 unit=AliasCode(id='AliasCode_237', extensionAttributes=[], standardCode=Code(id='Code_578', extensionAttributes=[], code='C29848', codeSystem='http://www.cdisc.org', codeSystemVersion='2024-09-27', decode='Year', instanceType='Code'), standardCodeAliases=[], instanceType='AliasCode') instanceType='Quantity'</p></td></tr><tr><td style=\"vertical-align: top; text-align: left\"><p>2</p></td><td style=\"vertical-align: top; text-align: left\"><p>Patients with Probable Mild to Moderate Alzheimer's Disease as defined by the NINCDS and the ADRDA guidelines (Attachment LZZT.7)</p></td></tr><tr><td style=\"vertical-align: top; text-align: left\"><p>3</p></td><td style=\"vertical-align: top; text-align: left\"><p>MMSE score of 10 to 23</p></td></tr></table></div>"
            },
            "section": []
          },
          {
            "title": "Exclusion Criteria",
            "code": {
              "text": "section5.4-exclusion-criteria"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Patients may be excluded in the study for <strong>any</strong> of the following reasons:</p><table><tr><td style=\"vertical-align: top; text-align: left\"><p>9</p></td><td style=\"vertical-align: top; text-align: left\"><p>Persons who have previously completed or withdrawn from this study or any other study investigating xanomeline TTS or the oral formulation of xanomeline.</p></td></tr></table></div>"
            },
            "section": []
          },
          {
            "title": "Lifestyle Considerations",
            "code": {
              "text": "section5.5-lifestyle-considerations"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Meals and Dietary Restrictions",
            "code": {
              "text": "section5.5.1-meals-and-dietary-restrictions"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Caffeine, Alcohol, Tobacco, and Other Habits",
            "code": {
              "text": "section5.5.2-caffeine,-alcohol,-tobacco,-and-other-habits"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Not applicable</p></div>"
            },
            "section": []
          },
          {
            "title": "Physical Activity",
            "code": {
              "text": "section5.5.3-physical-activity"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Other Activity",
            "code": {
              "text": "section5.5.4-other-activity"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Screen Failures",
            "code": {
              "text": "section5.6-screen-failures"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "TRIAL INTERVENTION AND CONCOMITANT THERAPY",
            "code": {
              "text": "section6-trial-intervention-and-concomitant-therapy"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Description of Trial Intervention",
            "code": {
              "text": "section6.1-description-of-trial-intervention"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Rationale for Trial Intervention",
            "code": {
              "text": "section6.2-rationale-for-trial-intervention"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Dosing and Administration",
            "code": {
              "text": "section6.3-dosing-and-administration"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Trial Intervention Dose Modification",
            "code": {
              "text": "section6.3.1-trial-intervention-dose-modification"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Treatment of Overdose",
            "code": {
              "text": "section6.4-treatment-of-overdose"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Preparation, Handling, Storage and Accountability",
            "code": {
              "text": "section6.5-preparation,-handling,-storage-and-accountability"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Preparation of Trial Intervention",
            "code": {
              "text": "section6.5.1-preparation-of-trial-intervention"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Handling and Storage of Trial Intervention",
            "code": {
              "text": "section6.5.2-handling-and-storage-of-trial-intervention"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Accountability of Trial Intervention",
            "code": {
              "text": "section6.5.3-accountability-of-trial-intervention"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Participant Assignment, Randomisation and Blinding",
            "code": {
              "text": "section6.6-participant-assignment,-randomisation-and-blinding"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Participant Assignment",
            "code": {
              "text": "section6.6.1-participant-assignment"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Randomisation",
            "code": {
              "text": "section6.6.2-randomisation"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Blinding and Unblinding",
            "code": {
              "text": "section6.6.3-blinding-and-unblinding"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The study will be double-blind. To further preserve the blinding of the study, only a minimum number of Lilly and CRO personnel will see the randomization table and codes before the study is complete.</p><p>Emergency codes generated by a computer drug-labeling system will be available to the investigator. These codes, which reveal the patients treatment group, may be opened during the study only if the choice of follow-up treatment depends on the patient\u2019s therapy assignment.</p><p>The investigator should make every effort to contact the clinical research physician prior to unblinding a patient\u2019s therapy assignment. If a patient\u2019s therapy assignment is unblinded, Lilly must be notified immediately by telephone. After the study, the investigator must return all sealed and any opened codes.</p></div>"
            },
            "section": []
          },
          {
            "title": "Trial Intervention Compliance",
            "code": {
              "text": "section6.7-trial-intervention-compliance"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Concomitant Therapy",
            "code": {
              "text": "section6.8-concomitant-therapy"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Prohibited Concomitant Therapy",
            "code": {
              "text": "section6.8.1-prohibited-concomitant-therapy"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Permitted Concomitant Therapy",
            "code": {
              "text": "section6.8.2-permitted-concomitant-therapy"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Rescue Therapy",
            "code": {
              "text": "section6.8.3-rescue-therapy"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Other Therapy",
            "code": {
              "text": "section6.8.4-other-therapy"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL",
            "code": {
              "text": "section7-discontinuation-of-trial-intervention-and-participant-withdrawal-from-trial"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Discontinuation of Trial Intervention",
            "code": {
              "text": "section7.1-discontinuation-of-trial-intervention"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Criteria for Permanent Discontinuation of Trial Intervention",
            "code": {
              "text": "section7.1.1-criteria-for-permanent-discontinuation-of-trial-intervention"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Temporary Discontinuation or Interruption of Trial Intervention",
            "code": {
              "text": "section7.1.2-temporary-discontinuation-or-interruption-of-trial-intervention"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Rechallenge",
            "code": {
              "text": "section7.1.3-rechallenge"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Participant Withdrawal from the Trial",
            "code": {
              "text": "section7.2-participant-withdrawal-from-the-trial"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Lost to Follow-Up",
            "code": {
              "text": "section7.3-lost-to-follow-up"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Trial Stopping Rules",
            "code": {
              "text": "section7.4-trial-stopping-rules"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "TRIAL ASSESSMENTS AND PROCEDURES",
            "code": {
              "text": "section8-trial-assessments-and-procedures"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Screening/Baseline Assessments and Procedures",
            "code": {
              "text": "section8.1-screening/baseline-assessments-and-procedures"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Efficacy Assessments and Procedures",
            "code": {
              "text": "section8.2-efficacy-assessments-and-procedures"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Safety Assessments and Procedures",
            "code": {
              "text": "section8.3-safety-assessments-and-procedures"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Physical Examination",
            "code": {
              "text": "section8.3.1-physical-examination"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Vital Signs",
            "code": {
              "text": "section8.3.2-vital-signs"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Electrocardiograms",
            "code": {
              "text": "section8.3.3-electrocardiograms"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Clinical Laboratory Assessments",
            "code": {
              "text": "section8.3.4-clinical-laboratory-assessments"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Suicidal Ideation and Behaviour Risk Monitoring",
            "code": {
              "text": "section8.3.5-suicidal-ideation-and-behaviour-risk-monitoring"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Adverse Events and Serious Adverse Events",
            "code": {
              "text": "section8.4-adverse-events-and-serious-adverse-events"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Definitions of AE and SAE",
            "code": {
              "text": "section8.4.1-definitions-of-ae-and-sae"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Time Period and Frequency for Collecting AE and SAE Information",
            "code": {
              "text": "section8.4.2-time-period-and-frequency-for-collecting-ae-and-sae-information"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Identifying AEs and SAEs",
            "code": {
              "text": "section8.4.3-identifying-aes-and-saes"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Recording of AEs and SAEs",
            "code": {
              "text": "section8.4.4-recording-of-aes-and-saes"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Follow-up of AEs and SAEs",
            "code": {
              "text": "section8.4.5-follow-up-of-aes-and-saes"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Reporting of SAEs",
            "code": {
              "text": "section8.4.6-reporting-of-saes"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Regulatory Reporting Requirements for SAEs",
            "code": {
              "text": "section8.4.7-regulatory-reporting-requirements-for-saes"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Serious and Unexpected Adverse Reaction Reporting",
            "code": {
              "text": "section8.4.8-serious-and-unexpected-adverse-reaction-reporting"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Adverse Events of Special Interest",
            "code": {
              "text": "section8.4.9-adverse-events-of-special-interest"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Disease-related Events or Outcomes Not Qualifying as AEs or SAEs",
            "code": {
              "text": "section8.4.10-disease-related-events-or-outcomes-not-qualifying-as-aes-or-saes"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Pregnancy and Postpartum Information",
            "code": {
              "text": "section8.5-pregnancy-and-postpartum-information"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Participants Who Become Pregnant During the Trial",
            "code": {
              "text": "section8.5.1-participants-who-become-pregnant-during-the-trial"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Participants Whose Partners Become Pregnant",
            "code": {
              "text": "section8.5.2-participants-whose-partners-become-pregnant"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Medical Device Product Complaints for Drug/Device Combination Products",
            "code": {
              "text": "section8.6-medical-device-product-complaints-for-drug/device-combination-products"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Definition of Medical Device Product Complaints",
            "code": {
              "text": "section8.6.1-definition-of-medical-device-product-complaints"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Recording of Medical Device Product Complaints",
            "code": {
              "text": "section8.6.2-recording-of-medical-device-product-complaints"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Time Period and Frequency for Collecting Medical Device Product Complaints .",
            "code": {
              "text": "section8.6.3-time-period-and-frequency-for-collecting-medical-device-product-complaints-."
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Follow-Up of Medical Device Product Complaints",
            "code": {
              "text": "section8.6.4-follow-up-of-medical-device-product-complaints"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Regulatory Reporting Requirements for Medical Device Product Complaints",
            "code": {
              "text": "section8.6.5-regulatory-reporting-requirements-for-medical-device-product-complaints"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Pharmacokinetics",
            "code": {
              "text": "section8.7-pharmacokinetics"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Genetics",
            "code": {
              "text": "section8.8-genetics"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Biomarkers",
            "code": {
              "text": "section8.9-biomarkers"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Immunogenicity Assessments",
            "code": {
              "text": "section8.1-immunogenicity-assessments"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Medical Resource Utilisation and Health Economics",
            "code": {
              "text": "section8.1.1-medical-resource-utilisation-and-health-economics"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "STATISTICAL CONSIDERATIONS",
            "code": {
              "text": "section9-statistical-considerations"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Analysis Sets",
            "code": {
              "text": "section9.1-analysis-sets"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Analyses Supporting Primary Objective(s)",
            "code": {
              "text": "section9.2-analyses-supporting-primary-objective(s)"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Statistical Model, Hypothesis, and Method of Analysis",
            "code": {
              "text": "section9.2.1-statistical-model,-hypothesis,-and-method-of-analysis"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Handling of Intercurrent Events of Primary Estimand(s)",
            "code": {
              "text": "section9.2.2-handling-of-intercurrent-events-of-primary-estimand(s)"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Handling of Missing Data",
            "code": {
              "text": "section9.2.3-handling-of-missing-data"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Sensitivity Analysis",
            "code": {
              "text": "section9.2.4-sensitivity-analysis"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Supplementary Analysis",
            "code": {
              "text": "section9.2.5-supplementary-analysis"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Analysis Supporting Secondary Objective(s)",
            "code": {
              "text": "section9.3-analysis-supporting-secondary-objective(s)"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Analysis of Exploratory Objective(s)",
            "code": {
              "text": "section9.4-analysis-of-exploratory-objective(s)"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Safety Analyses",
            "code": {
              "text": "section9.5-safety-analyses"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Other Analyses",
            "code": {
              "text": "section9.6-other-analyses"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Interim Analyses",
            "code": {
              "text": "section9.7-interim-analyses"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Sample Size Determination",
            "code": {
              "text": "section9.8-sample-size-determination"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Protocol Deviations",
            "code": {
              "text": "section9.9-protocol-deviations"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT",
            "code": {
              "text": "section10-general-considerations:-regulatory,-ethical,-and-trial-oversight"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Regulatory and Ethical Considerations",
            "code": {
              "text": "section10.1-regulatory-and-ethical-considerations"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Committees",
            "code": {
              "text": "section10.2-committees"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Informed Consent Process",
            "code": {
              "text": "section10.3-informed-consent-process"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Data Protection",
            "code": {
              "text": "section10.4-data-protection"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Early Site Closure or Trial Termination",
            "code": {
              "text": "section10.5-early-site-closure-or-trial-termination"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE",
            "code": {
              "text": "section11-general-considerations:-risk-management-and-quality-assurance"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Quality Tolerance Limits",
            "code": {
              "text": "section11.1-quality-tolerance-limits"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Data Quality Assurance",
            "code": {
              "text": "section11.2-data-quality-assurance"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Source Data",
            "code": {
              "text": "section11.3-source-data"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY",
            "code": {
              "text": "section12-appendix:-adverse-events-and-serious-adverse-events---definitions,-severity,-and-causality"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Further Details and Clarifications on the AE Definition",
            "code": {
              "text": "section12.1-further-details-and-clarifications-on-the-ae-definition"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Further Details and Clarifications on the SAE Definition",
            "code": {
              "text": "section12.2-further-details-and-clarifications-on-the-sae-definition"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Severity",
            "code": {
              "text": "section12.3-severity"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Causality",
            "code": {
              "text": "section12.4-causality"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS",
            "code": {
              "text": "section13-appendix:-definitions-and-supporting-operational-details"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Contraception and Pregnancy Testing",
            "code": {
              "text": "section13.1-contraception-and-pregnancy-testing"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Definitions Related to Childbearing Potential",
            "code": {
              "text": "section13.1.1-definitions-related-to-childbearing-potential"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Contraception",
            "code": {
              "text": "section13.1.2-contraception"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Pregnancy Testing",
            "code": {
              "text": "section13.1.3-pregnancy-testing"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Clinical Laboratory Tests",
            "code": {
              "text": "section13.2-clinical-laboratory-tests"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Country/Region-Specific Differences",
            "code": {
              "text": "section13.3-country/region-specific-differences"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "Prior Protocol Amendments",
            "code": {
              "text": "section13.4-prior-protocol-amendments"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "APPENDIX: GLOSSARY OF TERMS",
            "code": {
              "text": "section14-appendix:-glossary-of-terms"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          },
          {
            "title": "APPENDIX: REFERENCES",
            "code": {
              "text": "section15-appendix:-references"
            },
            "text": {
              "status": "generated",
              "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
            },
            "section": []
          }
        ]
      }
    }
  ]
}